Premium
Moxifloxacin for the treatment of pulmonary tuberculosis in children: A single center experience
Author(s) -
Garazzino Silvia,
Scolfaro Carlo,
Raffaldi Irene,
Barbui Anna Maria,
Luccoli Luigi,
Tovo PierAngelo
Publication year - 2014
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.22755
Subject(s) - moxifloxacin , medicine , tolerability , regimen , pediatrics , adverse effect , psychomotor learning , antibiotics , cognition , psychiatry , microbiology and biotechnology , biology
Objective To report our experience on the safety and tolerability of moxifloxacin for treating children affected by pulmonary TB. Study Design Children receiving a moxifloxacin‐containing anti‐TB regimen were included in the study. Their medical records were revised at the end of follow‐up. Methods We describe nine children treated with moxifloxacin for pulmonary TB at Regina Margherita Children's Hospital (Turin, Italy) between 2007 and 2012. Moxifloxacin was administered orally at 10 mg/kg/day once daily (maximum dose = 400 mg/day) following World Health Organization indications. During treatment, patients were systematically assessed for the development of side effects. Results Eight children were considered cured at the end of treatment; one child was lost to follow‐up after 3 months of treatment. Two children had side effects during treatment: one developed arthritis of the ankle; the other had liver toxicity, whose relationship with moxifloxacin could not be ruled out. We did not observe any case of QT prolongation, central nervous system disorders, growth defects or gastrointestinal disturbances. Conclusions A moxifloxacin‐containing regimen might be considered for the treatment of TB in children, especially for drug‐resistant and extensive forms. However, vigilance for possible side effects is recommended, especially if other drugs are concomitantly used. Studies on wider populations are needed to better define the impact of long‐term treatments with quinolones on children's growth and psychomotor development and to outline regulatory indications on moxifloxacin use in the pediatric setting. Pediatr Pulmonol. 2014; 49:372–376. © 2013 Wiley Periodicals, Inc.